Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glycinebetaine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycinebetaine SCHEMBL1712631 | 0.88 | LMNA (0.58) | TSHRLMNAALDH1A1APEX1THRB | |
| Glycinebetaine SCHEMBL75899 | 0.85 | TSHR (0.52) | TSHRLMNAALDH1A1APEX1KMT2A | |
| Glycinebetaine SCHEMBL7521843 | 0.84 | TSHR (0.43) | TSHRLMNAALDH1A1APEX1KMT2A | |
| Glycinebetaine SCHEMBL618945 | 0.83 | TSHR (0.50) | TSHRLMNAALDH1A1APEX1GABRR1 | |
| Glycinebetaine SCHEMBL18301505 | 0.83 | TSHR (0.50) | TSHRLMNAALDH1A1APEX1BLM | |
| Adipic Acid SCHEMBL5474223 | 0.83 | TSHR (0.50) | TSHRLMNAALDH1A1APEX1KMT2A | |
| Glycinebetaine SCHEMBL9452080 | 0.81 | FFAR3 (0.56) | TSHRLMNAALDH1A1APEX1KMT2A | |
| Glycinebetaine SCHEMBL6673018 | 0.80 | TSHR (0.50) | TSHRLMNAALDH1A1APEX1KMT2A | |
| Glycinebetaine SCHEMBL9281697 | 0.79 | TSHR (0.55) | TSHRLMNAALDH1A1APEX1KMT2A | |
| Glycinebetaine SCHEMBL9116728 | 0.79 | TSHR (0.48) | TSHRLMNAALDH1A1APEX1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025129289-A1 | METHODS FOR TREATING KERATIN FIBERS IN A LIGHTENING PROCESS | L'OREAL (FR) | 2025-06-26 | — | — | WO | claimed |
| WO-2025129302-A1 | COMPOSITION FOR TREATING KERATIN FIBERS AND METHOD FOR TREATING KERATIN FIBERS | L'OREAL (FR) | 2025-06-26 | — | — | WO | claimed |
| WO-2025129295-A1 | COMPOSITIONS AND METHODS FOR TREATING HAIR | L'OREAL (FR) | 2025-06-26 | — | — | WO | claimed |
| WO-2025129293-A1 | METHODS FOR TREATING KERATIN FIBERS WITH OSMOLYTES, CARBOXYLIC ACID AND AMINO ACIDS | L'OREAL (FR) | 2025-06-26 | — | — | WO | claimed |
| WO-2025129290-A1 | METHODS FOR TREATING KERATIN FIBERS IN A DYEING PROCESS | L'OREAL (FR) | 2025-06-26 | — | — | WO | claimed |
| WO-2025132533-A1 | COMPOSITION COMPRISING AN ALIPHATIC ACID OR SALT THEREOF, AN ANTIOXIDANT, A SPECIFIC COMPOUND SUCH AS BETAINE AND AT LEAST ONE PYRIDINE DERIVATIVE | L'OREAL (FR) | 2025-06-26 | — | — | WO | claimed |
| WO-2025129283-A1 | METHODS FOR TREATING KERATIN FIBERS | L'OREAL (FR) | 2025-06-26 | — | — | WO | claimed |
| WO-2025129303-A1 | METHODS FOR TREATING KERATIN FIBERS WITH OSMOLYTES, CARBOXYLIC ACIDS AND AMINO ACIDS | L'OREAL (FR) | 2025-06-26 | — | — | WO | claimed |
| WO-2025129291-A1 | METHODS FOR TREATING KERATIN FIBERS WITH OSMOLYTES, CARBOXYLIC ACID AND AMINO ACIDS | L'OREAL (FR) | 2025-06-26 | — | — | WO | claimed |
| WO-2025129287-A1 | METHODS FOR TREATING KERATIN FIBERS | L'OREAL (FR) | 2025-06-26 | — | — | WO | claimed |
| US-10085960-B2 | Methods and compositions for reducing ocular discomfort | BRIEN HOLDEN VISION INSTITUTE (AU) | 2018-10-02 | — | — | US | claimed |
| US-20150164844-A1 | METHODS AND COMPOSITIONS FOR REDUCING OCULAR DISCOMFORT | BRIEN HOLDEN VISION INSTITUTE (AU) | 2015-06-18 | — | — | US | claimed |
| WO-2013142912-A1 | METHODS AND COMPOSITIONS FOR REDUCING OCULAR DISCOMFORT | BRIEN HOLDEN VISION INSTITUTE (AU) | 2013-10-03 | — | — | WO | claimed |
| EP-1446096-A1 | TOPICAL COMPOSITIONS CONTAINING ENZYMES STABILISED WITH INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2004-08-18 | — | — | EP | claimed |
| EP-1446090-A2 | COMPOSITIONS CONTAINING ENZYMES STABILIZED WITH CERTAIN OSMO-PROTECTANTS AND METHODS FOR USING SUCH COMPOSITIONS IN PERSONAL CARE | THE PROCTER & GAMBLE COMPANY (US) | 2004-08-18 | — | — | EP | claimed |
| US-20030175232-A1 | Compositions containing enzymes stabilized with certain osmo-protectants and methods for using such compositions in personal care | THE PROCTER & GAMBLE COMPANY | 2003-09-18 | — | — | US | claimed |
| US-20030157088-A1 | Compositions containing enzymes stabilized with inhibitors having certain binding properties and methods for using such compositions in personal care | THE PROCTOR & GAMBLE COMPANY | 2003-08-21 | — | — | US | claimed |
| WO-2003041680-A1 | TOPICAL COMPOSITIONS CONTAINING ENZYMES STABILIZED WITH INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-05-22 | — | — | WO | claimed |
| WO-2003041667-A2 | COMPOSITIONS CONTAINING ENZYMES STABILIZED WITH CERTAIN OSMO-PROTECTANTS AND METHODS FOR USING SUCH COMPOSITIONS IN PERSONAL CARE | THE PROCTER & GAMBLE COMPANY (US) | 2003-05-22 | — | — | WO | claimed |
| US-5972840-A | Osmolyte regulator | AB TALL (HOLDINGS) PTY. LTD. (AU) | 1999-10-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030175232-A1 | Compositions containing enzymes stabilized with certain osmo-protectants and methods for using such compositions in personal care | TREH, CUTA, LPO | TSHR 3649/4885LMNA 1798/4885ALDH1A1 135/4885 |
| US-20030157088-A1 | Compositions containing enzymes stabilized with inhibitors having certain binding properties and methods for using such compositions in personal care | CUTA, LCT, TYR | TSHR 4356/4885LMNA 599/4885ALDH1A1 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.